- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02363062
Identification of New FTLD Genes (FTLD-Exome)
Identification of New Genes Causing Frontotemporal Lobar Degeneration by Whole Exome Sequencing and Characterization of the Associated Phenotypes
The major objective of the project is to map/identify new loci/genes, by a combination of whole exome sequencing and genome-wide linkage in autosomal dominant FTLD families excluded for known mutations.
Several secondary goals will be attained in the course of during the project:
For each novel gene identified in this project, we will determine the spectrum of mutations, evaluate their frequency and characterize the associated phenotypes. This will allow us to establish genotype-phenotype correlations in a large number of families, which will improve the nosology of these disorders and the diagnostic procedures;
Study Overview
Status
Conditions
Detailed Description
Background and justification of the research. In France, 6,000 to 8,000 patients are affected by frontotemporal lobar degeneration (FTLD). FTLD are degenerative dementias related to Alzheimer's disease, characterized by behavioural, language and cognitive disorders beginning in the sixth decade. The genetic forms of FTLD are frequent (30-50% of the patients), but the genes responsible for 30-40% of familial FTLD are still unknown. At present, no molecular diagnosis can be proposed for 30% of the FTLD families and patients, for which the responsible genes are still unknown. No presymptomatic testing can be proposed either to at-risk relatives in these families.
Objectives.
- The principal objective of this proposal is to identify one or several genes responsible for FTLD.
The secondary objectives are to:
- evaluate the relative frequency of identified genes;
- describe the phenotypes associated with the mutations in these genes;
- establish phenotype-genotype correlations in order to improve the diagnostic procedures and strategies;
- develop new genetic diagnostic analyses in the near future.
Project The patients will be recruited in three hospitals (Paris Salpetriere, Limoges, Lille). These three centers are partners of a national clinico-genetic network of 20 french centers experts in FTLD/FTLD-ALS, coordinated by Dr. I Le Ber. The participants in this network have collaborated for the last 15 years, and have already recruited over 1,000 patients with FTLD. Sequencing of known genes in these families allowed the identification of 150 families with an autosomal dominant form of FTLD not associated with a known mutation. Through the network, we aim to recruit 400 new patients with FTLD during the 4 years of the project. This estimation is based on the annual recruitment of the network during the last two years.
In this project, the 30 most informative families will be extended (440 patients and relatives sampled).
The combination of whole exome sequencing with genetic linkage studies in FTLD families without known mutations, and the large number of families included in this project, are two major points that should lead to the identification of several new genes. When causative genes are identified, we will establish the frequencies of mutations, extend the mutational spectrum, describe the clinical phenotypes and establish phenotype-genotype correlations. Genetic parameters such as penetrance will be analyzed.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Isabelle LE BER, MD, PhD
- Phone Number: (+33) 01 57 27 46 79
- Email: isabelle.leber@upmc.fr
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- Pitié Salpétrière Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Patients are included if they:
i) are affected by FTLD±ALS according to the international diagnosis criteria and ii) Have (or their legal representatives have) given signed written informed consent for the research.
iii) are affiliated to social security or beneficiary of such régime
Relatives are included if they:
i) are aged >18 years and ii) Have signed an informed consent for the research. are affiliated to social security or beneficiary of such
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
whole exome sequencing
Time Frame: Day 1
|
genes responsible for FTLD /Blood samples will be collected by a nurse, during a single consultation or hospitalization
|
Day 1
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Ceslis A, Argall R, Henderson RD, McCombe PA, Robinson GA. The spectrum of language impairments in amyotrophic lateral sclerosis. Cortex. 2020 Nov;132:349-360. doi: 10.1016/j.cortex.2020.09.003. Epub 2020 Sep 18.
- Didic M, Aglieri V, Tramoni-Negre E, Ronat L, Le Ber I, Ceccaldi M, Belin P, Felician O. Progressive phonagnosia in a telephone operator carrying a C9orf72 expansion. Cortex. 2020 Nov;132:92-98. doi: 10.1016/j.cortex.2020.05.022. Epub 2020 Aug 10.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-A00157-40
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frontotemporal Lobar Degeneration
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedTauopathies | Frontotemporal Dementia (FTD) | Frontotemporal Lobar Degeneration (FTLD)United States
-
University of PennsylvaniaEnrolling by invitationFrontotemporal Degeneration | Frontotemporal Dementia | Frontotemporal Dementia, Behavioral Variant | FTDUnited States
-
National Institute of Mental Health (NIMH)CompletedDementia | Frontotemporal Lobar DegenerationUnited States
-
University Hospital, BordeauxCompletedFrontotemporal Lobar DegenerationFrance
-
Nantes University HospitalCompletedFrontotemporal Lobar DegenerationFrance
-
University of California, San FranciscoForest LaboratoriesCompletedFrontotemporal Lobar Degeneration
-
University of California, San FranciscoTerminatedNonfluent Aphasia, Progressive | Primary Tauopathies | Corticobasal Degeneration Syndrome | Frontotemporal Lobar Degeneration With Tau Inclusions | MAPT Mutation Carriers, Symptomatic | Traumatic Encephalopathy SyndromeUnited States
-
University of California, Los AngelesNational Institute on Aging (NIA)UnknownFrontotemporal Degeneration | Frontotemporal Dementia | Alzheimer's Disease | Social BehaviorUnited States
-
Ludwig-Maximilians - University of MunichRecruitingNeurodegenerative Diseases | Frontotemporal DegenerationGermany
-
BiogenCompletedFrontotemporal Dementia | Behavioral Variant Frontotemporal DementiaUnited States